Molecure (MOC) Q3 2024 earnings summary

Executive summary

• Molecure focuses on R&D of small-molecule drugs for oncology, fibrotic, and inflammatory diseases, with a pipeline led by OATD-01 (phase II) and OATD-02 (phase I).

• The business model is based on partnering, milestone payments, and royalties, with a hybrid approach for mRNA-targeting programs.

• Strategic priorities include advancing clinical programs, expanding the mRNA platform, and leveraging AI for drug discovery.

• The company reported a net loss and negative cash flow, reflecting high R&D investment and limited revenue from grants.

Financial highlights

• Revenue for Q1–Q3 2024 was PLN 1.12m, down from PLN 3.26m year-over-year, mainly from grants.

• Net loss for Q1–Q3 2024 was PLN -20.83m, compared to PLN -18.45m year-over-year.

• Operating expenses decreased to PLN 22.81m from PLN 25.23m year-over-year.

• Cash at period end was PLN 28.58m, down from PLN 63.99m at 2023 year-end.

• Negative operating cash flow of PLN -22.22m and investing cash flow of PLN -18.35m for Q1–Q3 2024.

Outlook and guidance

• Results in the next quarter will depend on clinical and preclinical program progress, grant acquisition, and business development partnerships.

• The company plans to secure additional funding of approx. PLN 62m to complete clinical trials and early-stage projects.

• Strategic goals for 2024–2025 include clinical milestones for OATD-01 and OATD-02, mRNA platform partnering, and AI-driven efficiency gains.